SynAct Pharma AB (CHIX:SYNACS) Beginning Cash Position: kr65.78 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SYNACS SynAct Pharma AB CHIX:SYNACS
9 GF Score
Price kr18.62
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Beginning Cash Position?

SynAct Pharma AB CHIX:SYNACS 9 Beginning Cash Position is kr65.78 Mil as of Jun. 2026. GuruFocus rates CHIX:SYNACS with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

SynAct Pharma AB's Beginning Cash Position for the quarter that ended in Jun. 2026 was kr65.78 Mil.

SynAct Pharma AB's quarterly Beginning Cash Position declined from Dec. 2025 (kr77.94 Mil) to Mar. 2026 (kr53.41 Mil) but then increased from Mar. 2026 (kr53.41 Mil) to Jun. 2026 (kr65.78 Mil).

SynAct Pharma AB's annual Beginning Cash Position declined from Dec. 2023 (kr108.25 Mil) to Dec. 2024 (kr62.39 Mil) and declined from Dec. 2024 (kr62.39 Mil) to Dec. 2025 (kr61.21 Mil).

SynAct Pharma AB Beginning Cash Position Related Terms

SynAct Pharma AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Beginning Cash Position Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.55 24.00 108.25 62.39 61.21

SynAct Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.16 68.89 77.94 53.41 65.78
CHIX:SYNACS
9GF Score
SynAct Pharma AB CHIX:SYNACS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr65.78 Mil mean?
SynAct Pharma AB (CHIX:SYNACS) has a Beginning Cash Position of kr65.78 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's Beginning Cash Position too high?
SynAct Pharma AB's current Beginning Cash Position is kr65.78 Mil. Overall, SynAct Pharma AB has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Beginning Cash Position compare to VRTX and REGN?
SynAct Pharma AB's Beginning Cash Position of kr65.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current Beginning Cash Position is kr65.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (CHIX:SYNACS) has a current Beginning Cash Position of kr65.78 Mil. The current Beginning Cash Position is kr65.78 Mil. SynAct Pharma AB's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For SynAct Pharma AB (CHIX:SYNACS), the current Beginning Cash Position is kr65.78 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges SYNACT:Sweden8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
9GF Score

Get the complete analysis for CHIX:SYNACS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.62
Price